Kopra Bio key facts
- Operator of a biological therapy platform intended for medical treatment.
- It has raised $600K across 1 recorded rounds; the latest was Early Stage VC in Oct 2025.
- Notable investors include Y Combinator, Andreessen Horowitz, Pioneer Fund, Metaplanet Holdings, University of California — 18 tracked in total.
- Status: Privately Held (backing).
Who backs Kopra Bio
18+- ·The complete investor list: 18 names
- ·Watch Kopra Bio: the Monday email on marks, rounds and moves
Kopra Bio funding rounds
1 roundsHow much has Kopra Bio raised?
Kopra Bio has raised $600,000 in total; 1 of its rounds is on record. The most recent was an early-stage round in Oct 2025.
Kopra Bio investors
18 investors are on record for Kopra Bio, including Y Combinator, Andreessen Horowitz, Pioneer Fund and Metaplanet Holdings. By type, the record holds 7 venture capital firms. The early-stage round in Oct 2025 drew 12 investors.
About Kopra Bio
Operator of a biological therapy platform intended for medical treatment. The company's platform uses engineered biological agents capable of selectively targeting diseased cells, reprogramming them to produce immune-stimulating factors and engage the body's own defenses, with features including selective delivery mechanisms, modulation of immune responses, integration with existing therapeutic strategies, and adaptability to research and clinical development, enabling the oncology and biomedical research market to explore approaches to treating aggressive diseases and potentially improve long-term therapeutic outcomes and patient responses.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 10
- Website
- kopra.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Kopra Bio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.